Soren Weis Dahl

Soren Weis Dahl, PhD, MBA


Dr. Soren Weis Dahl is a biotech executive whose career-long life science and business experience in the US and Europe includes various leadership positions in biotech and pharma, strategy and business development and biotech consulting. Most recently, Dr. Dahl was the CEO of the orphan drug start-up Prophylix and led the sale of the company’s assets to the US orphan drug specialist Rallybio. One of Prophylix’s former assets, RLYB211, is now Rallybio’s lead project. Dr. Dahl received his M.Sc. in Chemical Engineering and PhD in protein chemistry from the Technical University of Denmark and his MBA from Copenhagen Business School.